SAB Biotherapeutics reports update to phase 3 NIH ACTIV-2 trial design evaluating SAB-185 for Covid-19 treatment
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, announced an update to the design of the ongoing phase 3 ACTIV-2 trial evaluating the clinical efficacy and safety of SAB-185 for the treatment of participants with mild-moderate Covid infections at higher risk for progression to hospitalization. The phase 3 trial had been designed as an open-label, randomized non-inferiority study comparing SAB-185 to an active comparator
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
